by TractManager | Aug 5, 2019 | Emerging Technology Report
Turalio (pexidartinib) is an oral small molecule kinase inhibitor of colony stimulating factor-1 receptor (CSF1R) for treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations, and...
by TractManager | Aug 1, 2019 | Emerging Technology Report
Nubeqa is a nonsteroidal second-generation androgen receptor inhibitor that competes with androgen by binding to the androgen receptor. It reduces the ability of androgen to promote the growth of prostate cancer cells. Nubeqa is indicated for the treatment of patients...
by TractManager | Aug 1, 2019 | Clinical Utility Evaluation
This report evaluates the of genetic testing for common forms of hereditary thrombophilia in pediatric patients with unprovoked venous thromboembolism (VTE).If you have a Hayes login, click here to view the full report on the Knowledge Center.
by TractManager | Aug 1, 2019 | Clinical Utility Evaluation
This report evaluates the of genetic testing for common forms of hereditary thrombophilia in pediatric patients with unprovoked venous thromboembolism (VTE).If you have a Hayes login, click here to view the full report on the Knowledge Center.
by TractManager | Aug 1, 2019 | Emerging Technology Report
Nubeqa is a nonsteroidal second-generation androgen receptor inhibitor that competes with androgen by binding to the androgen receptor. It reduces the ability of androgen to promote the growth of prostate cancer cells. Nubeqa is indicated for the treatment of patients...
Recent Comments